23 recruiting, 16 not yet recruiting, 10 completed, 8 active not recruiting. 29 Phase 2, 11 Phase 3, 8 Phase 1, 5 Not applicable.
Follow Esophageal Squamous Cell Carcinoma (ESCC): new trials by email Literature Review of Esophageal Squamous Cell Carcinoma (ESCC) trials Research Report on Esophageal Squamous Cell Carcinoma (ESCC)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Risk of Esophageal Cancer Returning After Immunotherapy, Chemotherapy, and Surgery Esophageal Squamous Cell Carcinoma (ESCC) | Not yet recruiting | Peking University Cancer Hospital & Institute | 100 | 2026-10-01 | 2026-09-16 | |
| Sacituzumab Tirumotecan (Sac-TMT/SKB264) Plus Tagitanlimab (KL-A167) in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma Sacituzumab Tirumotecan + Tagitanlimab - ESCC, Gastric Adenocarcinoma | Phase 2 | Not yet recruiting | Sun Yat-sen University | 75 | 2026-08-31 | 2026-07-14 |
| Neoadjuvant Chemoradiotherapy Versus Neoadjuvant Immunochemotherapy for Resectable Esophageal Cancer: A Target Trial Emulation Study Radiotherapy, Platinum-based Chemotherapy, PD-1 Inhibitor - Esophageal Squamous Cell Carcinoma (ESCC) | Not yet recruiting | Henan Cancer Hospital | 400 | 2026-08-20 | 2026-08-21 | |
| Neoadjuvant Chemoradiotherapy Combined With CTLA-4 Monoclonal Antibody Plus PD-1 Monoclonal Antibody for Locally Advanced Esophageal Cancer Ipilimumab (1mg/kg), Sinitilimab, Nab-paclitaxel + Cisplatin - Esophageal Squamous Cell Carcinoma (ESCC) | Phase 2 | Recruiting | Sun Yat-sen University | 51 | 2026-08-01 | 2026-08-07 |
| A Study of HS-20093 in Patients With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) HS-20093 for Injection, Irinotecan; Paclitaxel; Docetaxel - Esophageal Squamous Cell Carcinoma (ESCC) | Phase 3 | Not yet recruiting | Hansoh BioMedical R&D Company | 494 | 2026-07-31 | 2026-06-02 |
| Clinical Application of an AI-based Dissection Trajectory Prediction System (ADTPS) in Endoscopic Submucosal Dissection AI-based Dissection Trajectory Prediction System (ADTPS), Conventional ESD Procedure - Esophageal Squamous Cell Carcinoma (ESCC), High-Grade Intraepithelial Neoplasia | Not applicable | Active not recruiting | Qilu Hospital of Shandong University | 220 | 2026-07-29 | 2026-10-15 |
| PD-1 Inhibitors Combined With Local Therapy at Different Timings in Oligometastatic ESCC Two arms adopt local intervention administered at distinct timings. - Esophageal Squamous Cell Carcinoma (ESCC) | Recruiting | Fudan University | 354 | 2026-07-15 | 2026-07-13 | |
| Early Response-guided Sequential Radiotherapy After Chemoimmunotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma Neoadjuvant Chemoimmunotherapy (Tislelizumab Plus Paclitaxel and Cisplatin), Sequential Chemoradiotherapy - Esophageal Squamous Cell Carcinoma (ESCC) | Phase 2 | Not yet recruiting | Tianjin Medical University Cancer Institute and Hospital | 110 | 2026-07-14 | 2026-07-22 |
| Neoadjuvant Short-Course Radiotherapy Plus Tislelizumab and Chemotherapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma Albumin-bound paclitaxel, Low-dose Short-course Radiotherapy, High-dose Short-course Radiotherapy - Esophageal Squamous Cell Carcinoma (ESCC) | Phase 2 | Not yet recruiting | Tang-Du Hospital | 50 | 2026-07-10 | 2026-07-01 |
| TDLN-Guided Lymphadenectomy After Neoadjuvant Immunochemotherapy for ESCC Curative Esophagectomy With Systematic Lymphadenectomy - Esophageal Squamous Cell Carcinoma (ESCC) | Not yet recruiting | Tongji Hospital | 400 | 2026-07-01 | 2026-07-13 | |
| Phase II Study of Induction Chemoimmunotherapy Followed by Radiotherapy and Organ Preservation in Resectable ESCC Sugemalimab and Chemotherapy, Nab-paclitaxel, Cisplatin - Esophageal Squamous Cell Carcinoma (ESCC) | Phase 2 | Active not recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 140 | 2026-07-01 | 2026-07-17 |
| Adebrelimab Combined With Neoadjuvant Chemotherapy in Borderline Resectable Locally Advanced Esophageal Squamous Cell Carcinoma Adebrelimab Injection - Esophageal Squamous Cell Carcinoma (ESCC) | Phase 2 | Recruiting | Sun Yat-sen University | 42 | 2026-06-17 | 2026-06-10 |
| Low-Dose Radiotherapy With Retlirafusp Alfa and Chemotherapy as Neoadjuvant Therapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma Low-dose radiotherapy + Retlirafusp alfa + nab-paclitaxel + cisplatin/carboplatin, Retlirafusp alfa + nab-paclitaxel + cisplatin/carboplatin - Esophageal Squamous Cell Carcinoma (ESCC) | Phase 2 | Active not recruiting | Harbin Medical University | 96 | 2026-06-10 | 2026-07-02 |
| Adebrelimab Combined With Neoadjuvant Chemoradiotherapy for Esophageal Squamous Cell Carcinoma • Adebrelimab and nab-paclitaxel, carboplatin in Combination With radiotherapy - Esophageal Squamous Cell Carcinoma (ESCC) | Phase 2 | Recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 37 | 2026-05-22 | 2026-05-19 |
| QLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma QLC5508, Investigator's Choice of Chemotherapy (docetaxel, paclitaxel, or Irinotecan Hydrochloride) - Esophageal Squamous Cell Carcinoma (ESCC) | Phase 3 | Recruiting | Qilu Pharmaceutical Co., Ltd. | 466 | 2026-04-20 | 2026-04-24 |
| O-GlcNAcylation Induced HMGB1 Signalling specimen collection - Esophageal Squamous Cell Carcinoma (ESCC) | Active not recruiting | Chinese University of Hong Kong | 120 | 2026-04-01 | 2026-07-14 | |
| Stratified Treatment in Unresectable Locally Advanced ESCC Without Progression After Chemoimmunotherapy Induction Plus CCRT: Toripalimab Consolidation vs observation--a Prospective, Randomized, Controlled Phase III Multicenter Study Toripalimab - Esophageal Squamous Cell Carcinoma (ESCC) | Phase 3 | Recruiting | Tianjin Medical University Cancer Institute and Hospital | 340 | 2026-03-23 | 2026-10-23 |
| 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors 177Lu-BetaBart, BetaBart + unlabeled BetaBart - Castration-Resistant Prostate Cancer (CRPC), Colorectal Cancer | Phase 1 / Phase 2 | Recruiting | Radiopharm Theranostics, Ltd | 61 | 2026-02-23 | 2026-10-01 |
| Short-course Radiotherapy Combined With Serplulimab and Chemotherapy as Neoadjuvant Treatment for Resectable ESCC Serplulimab - Esophageal Squamous Cell Carcinoma (ESCC) | Phase 2 | Not yet recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 22 | 2026-02-15 | 2026-02-11 |
| Neoadjuvant Treatment of Toripalimab Combined With Nab-paclitaxel and Platinum Versus Neoadjuvant Docetaxel Combined With Cisplatin and 5-fluorouracil (DCF) in Esophageal Squamous Cell Carcinoma 3 cycles (Toripalimab + chemotherapy), 3 cycles（DCF） - Esophageal Squamous Cell Carcinoma (ESCC) | Phase 3 | Not yet recruiting | Tang-Du Hospital | 390 | 2026-02-01 | 2026-01-30 |
Showing 20 of 62. Sign in to see all of them.
Esophageal Squamous Cell Carcinoma (62) · Carcinoma, Non-Small-Cell Lung (4) · Esophageal Neoplasms (4) · Neoplasm Metastasis (3) · Squamous Cell Carcinoma of Head and Neck (3) · Adenocarcinoma Of Esophagus (2) · Colorectal Neoplasms (2) · Neoplasms (2) · Parkinson Disease 4, Autosomal Dominant Lewy Body (2) · Small Cell Lung Carcinoma (2) · Adenocarcinoma (1) · Anastomotic Leak (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Squamous Cell (1) · Cholangiocarcinoma (1)
Carcinoma (62) · Digestive System Diseases (62) · Digestive System Neoplasms (62) · Esophageal Diseases (62) · Gastrointestinal Diseases (62) · Neoplasms by Histologic Type (62) · Neoplasms by Site (62) · Neoplasms, Glandular and Epithelial (62) · Neoplasms, Squamous Cell (62) · Carcinoma, Squamous Cell (61) · Gastrointestinal Neoplasms (61) · Head and Neck Neoplasms (61) · Neoplasms (60) · Esophageal Neoplasms (58) · Pathological Conditions, Signs and Symptoms (7)
Cisplatin (12) · Paclitaxel (10) · Drug Therapy (8) · Radiotherapy (8) · Carboplatin (7) · tislelizumab (7) · 130-nm albumin-bound paclitaxel (6) · toripalimab (5) · Irinotecan (4) · Docetaxel (3) · Immune Checkpoint Inhibitors (3) · Neoadjuvant Therapy (3) · Surgical Procedures, Operative (3) · pembrolizumab (3) · Albumin-Bound Paclitaxel (2)
Sun Yat-sen University (4) · BeiGene (3) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (3) · Peking University Cancer Hospital & Institute (3) · Sichuan University (3) · Tianjin Medical University Cancer Institute and Hospital (3) · Merck Sharp & Dohme LLC (2) · Shanghai Chest Hospital (2) · Tang-Du Hospital (2) · The First Affiliated Hospital of Zhengzhou University (2) · Tongji Hospital (2) · Yongtao Han (2) · ALX Oncology Inc. (1) · AP Biosciences Inc. (1) · Beijing Konruns Pharmaceutical Co., Ltd. (1)
China (42) · France (7) · Taiwan (7) · United States (7) · South Korea (5) · Germany (4) · Italy (4) · Japan (4) · Belgium (3) · Spain (3) · United Kingdom (3) · Brazil (2) · Chile (2) · Czechia (2) · Denmark (2)
Ajay Goel, PhD (1) · Bin Zheng (1) · Hui Liu, Professor (1) · Kuaile Zhao, MD (1) · Lei Zhou, Master (1) · Li Feng, Ph.D. (1) · Tsang-Wu Liu (1) · Weihu Wang, MD (1)
PMID 40373876, PMID 12049861, PMID 26254683, PMID 26808342, PMID 29409469, PMID 29441562, PMID 29861116, PMID 31319389, PMID 32143580, PMID 33065643, PMID 33533655, PMID 34137505, PMID 34269067, PMID 34454674, PMID 35046059, PMID 35442766, PMID 35671803, PMID 35785595, PMID 36158679, PMID 36322089, PMID 37080222, PMID 37433041, PMID 37846080, PMID 38240916, PMID 38305608, PMID 38414510, PMID 39562407, PMID 40075024, PMID 40179324, PMID 40467307, PMID 41309527, PMID 41335329, PMID 41490111, PMID 41601631, PMID 42320980, PMID 42834033
2018 (2), 2017 (1), 2019 (1), 2023 (1)